ClinicalTrials.gg
RecruitingNCT06341335Updated Jun 24, 2024

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 3 interventional study of cadonilimab and pulocimab in Gastric and Gastroesophageal Junction Adenocarcinoma, sponsored by Akeso. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-24.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
506
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This randomized, multicenter, double-blind, phase 3 study will evaluate the efficacy and safety of the combination of cadonilimab (AK104) and pulocimab (AK109) and paclitaxel compared with paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma who failed first-line immunochemotherapy.

02

Conditions studied

  • Gastric and Gastroesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Age ≥ 18 years and ≤ 75 years
  3. or cytologically documented advanced unresectable or gastric adenocarcinoma or gastroesophageal Junction (GEJ) adenocarcinoma.
  4. Failed treatment with PD-(L)1 monoclonal antibody and standard chemotherapy
  5. At least one based on v1.1
  6. status of 0 or 1
  7. Estimated survival ≥ 3 months
  8. Adequate organ function per protocol-defined criteria
  9. Women of and men with female partners of childbearing potential must agree to use effective during treatment and for at least 120 days following the last dose of study treatment

Exclusion criteria

Exclusion Criteria:

  1. Mixed gastric or gastroesophageal Junction cancer containing other pathological components than adenocarcinoma
  2. -positive
  3. Known other invasive within 3 years
  4. Subjects who are currently participating in other interventional study
  5. Received prior systemic anti-tumour therapy within 4 weeks before randomization
  6. Previous systemic treatment with taxane within 6 months before randomization
  7. Previous systemic treatment targeting VEGF or anti-VEGFR signaling pathways
  8. In addition to anti-PD-(L)1 monoclonal antibody, prior exposure to other , immune checkpoint agonists, immune cell therapy or other therapy that targets anti-tumor immune mechanisms
  9. History of immune-related adverse effects leading to recommendation against reintroduction of immunotherapy or any condition dependency on systemic therapy with or agents within 14 days prior to randomization
  10. History of severe infection within 4 weeks prior to randomization
  11. Presence of central nervous system , , or spinal cord compression
  12. Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage
  13. History or presence of a serious hemorrhage or known bleeding tendency within 2 months before randomization
  14. Major surgical procedure or serious trauma within 28 days prior to randomization
  15. History of interstitial lung disease or noninfectious pneumonitis
  16. Active infectious diseases, including tuberculosis, infection, syphilis infection,or /C
  17. Known allergy to the antibody or any component of the study drug; Or the constitution of being allergic to multiple substances
  18. History of allogeneic organ transplantation or haematopoietic stem cell transplantation
  19. Toxicities of prior anticancer therapy have not resolved to ≤ Grade 1 ( version 5.0)
  20. Use of within 30 days prior to randomization
  21. Pregnant or lactating women.
  22. Any condition considered by the investigator to be inappropriate for enrollment
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
506 participants (estimated)

Study arms

  • Experimental
    Cadonilimab in combination with pulocimab and paclitaxel

    Cadonilimab (AK104) in combination with pulocimab (AK109) and paclitaxel, iv, every 3 weeks

    Drug: cadonilimab · Drug: pulocimab · Drug: paclitaxel

  • Active comparator
    Placebo in combination with paclitaxel

    Placebo in combination with Paclitaxel, iv, every 3 weeks

    Drug: paclitaxel · Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) assessed by blinded independent central review (BICR)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first (based on RECIST 1.1 criteria).

    Time frame: Up to 2 years

  2. Overall survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to 2 years

Secondary outcomes

  1. Progression-free survival (PFS) assessed by investigator

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first (based on RECIST 1.1 criteria).

    Time frame: Up to 2 years

  2. Objective Response Rate (ORR)

    ORR is defined as proportion of subjects who have a complete or partial response relative to baseline according to RECIST 1.1 criteria

    Time frame: Up to 2 years

  3. Duration of Response (DoR)

    DoR is defined as the duration from the first documentation of objective response to the first documented disease progression(based on RECIST v1.1 criteria) or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years

  4. Disease control rate (DCR)

    DCR is defined as the proportion of subjects with CR, PR, or SD (based on RECIST v1.1 criteria).

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Nov 2026, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2024
First posted
Apr 2, 2024
StartActual
Jun 19, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Jul 2027
Last update
Jun 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06341335
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Jun 19, 2024
Primary completion
Nov 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jun 24, 2024

Study contacts

Ting Liu
Contact
clinicaltrials@akesobio.com
+86(0760)8987 3999
Lin Shen, MD
principal investigator · Peking University Cancer Hospital & Institute
Xiaotian Zhang, MD
principal investigator · Peking University Cancer Hospital & Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cadonilimab · Pulocimab

Start the discussion